Clopidogrel dosage forms and strengths

Revision as of 16:39, 6 March 2014 by Gerald Chi (talk | contribs)
Jump to navigation Jump to search
Clopidogrel
PLAVIX® FDA Package Insert
Indications and Usage
Dosage and Administration
Dosage Forms and Strengths
Contraindications
Warnings and Precautions
Adverse Reactions
Drug Interactions
Use in Specific Populations
Overdosage
Description
Clinical Pharmacology
Nonclinical Toxicology
Clinical Studies
How Supplied/Storage and Handling
Patient Counseling Information
Labels and Packages
Clinical Trials on Clopidogrel
ClinicalTrials.gov

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Jesus Rosario Hernandez, M.D. [2]

Dosage Forms and Strengths

  • 75 mg tablets: Pink, round, biconvex, film-coated tablets debossed with "75" on one side and "1171" on the other
  • 300 mg tablets: Pink, oblong, film-coated tablets debossed with "300" on one side and "1332" on the other[1]

References

  1. "PLAVIX (CLOPIDOGREL BISULFATE) TABLET, FILM COATED [BRISTOL-MYERS SQUIBB/SANOFI PHARMACEUTICALS PARTNERSHIP]".

Adapted from the FDA Package Insert.